The therapeutic experience reported in the paper was conceived after the use of nimotuzumab and radiotherapy (BSCPED-05 international multicentric trial, EUDRACT 2005-003100-11) in 2009 when we decided to explore the activity of the same combination plus vinorelbine (see the paper for the rationale).
The company developing nimotuzumab in Europe agreed for its compassionate use in DIPG patients in this context.
The Ethical Committee (EC) of our Institution (Fondazione IRCCS Istituto Nazionale dei Tumori, in Milan) approved any single patient-case admission to the compassionate use of the combination of nimotuzumab with vinorelbine and radiotherapy, according to the procedure designed by the Italian Ministry of Health and by the national Agency for Drug Evaluation (AIFA).
The signed informed consent, approved by the EC, included the possibility of collecting and publishing data, according to the law, in an observational report.
Meanwhile, after some time (February 2012), an ancillary biological study on the same cohort of patients was in fact approved by the Ethical Committee also concerning the analysis of blood samples for biological research.
The original article can be found online at https ://doi.org/10.1007/ s1106 0-014-1428-z. In conclusion, our paper was a report of the clinical data from a cohort of patients treated in the context of a compassionate use approved as such.
As to the paper writing, we adopt a post-hoc analysis as a phase 2 study but we acknowledge as an ERRATUM that this was not a formal phase 2 study.
